Home » Stocks » NKTX

Nkarta, Inc. (NKTX)

Stock Price: $32.14 USD 1.37 (4.45%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $32.50 +0.36 (1.12%) Jul 23, 5:30 PM
Market Cap 1.05B
Revenue (ttm) 385
Net Income (ttm) -102.03M
Shares Out 32.82M
EPS (ttm) -4.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $32.14
Previous Close $30.77
Change ($) 1.37
Change (%) 4.45%
Day's Open 30.89
Day's Range 29.71 - 32.33
Day's Volume 137,972
52-Week Range 22.46 - 79.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Nkarta Therapeutics Inc (NASDAQ: NKTX) will be moving into an 88,000-square-foot facility that will not only serve as its newest headquarters but will support the research, development, and future comme...

1 week ago - Benzinga

SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today an...

1 week ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today an...

1 month ago - GlobeNewsWire

Unfortunately, this isn't an endorsement by a big drug developer.

Other stocks mentioned: CRSP
1 month ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today ann...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today rep...

2 months ago - GlobeNewsWire

Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all th...

Other stocks mentioned: CRSP
2 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today a...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat ...

3 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat c...

5 months ago - GlobeNewsWire

Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.

Other stocks mentioned: AVIR, JNJ, LEGN, LLY, RHHBY, RNA
5 months ago - GuruFocus

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat c...

8 months ago - GlobeNewsWire

First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat c...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat c...

8 months ago - GlobeNewsWire

Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business Officer Alicia J. Hager , J.D., Ph.D. to Join as Chief Legal Officer

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to trea...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to trea...

10 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...

11 months ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Other stocks mentioned: BBBY, PSTX, AKRO, AZZ, GSK, PRSP, TSE ...
1 year ago - Benzinga

Nkarta Inc. (NASDAQ: NKTX) announced on Tuesday the underwriters for its initial public offering have completely exercised their overallotment option to purchase 2.1 million additional shares.

1 year ago - Benzinga

Nkarta Inc. NKTX, -6.41% said late Tuesday it raised $289.8 million in its recent public offering after underwriters exercised all their options for shares to cover overallotments.

1 year ago - Market Watch

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $289.8 Million Underwriters’ Full Exercise of Option Brings Gross Proceeds to $289.8 Million

1 year ago - GlobeNewsWire

The Nkarta (NKTX) IPO is underway for the cancer research company and it has it offering 14 million shares on the Nasdaq. The post Nkarta IPO: 13 Things for Potential NKTX Stock Investors to Know appear...

1 year ago - InvestorPlace

Shares of Nkarta Inc. tripled out of the gate Friday, after the biotechnology company's initial public offering priced above its expected range.

1 year ago - Market Watch

Nkarta Inc. priced its initial public offering Friday at $18 a share, above its price range of $16 to $17, selling 14 million shares to raise about $252 million.

1 year ago - Market Watch

SOUTH SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer,...

1 year ago - GlobeNewsWire

About NKTX

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic synd... [Read more...]

Industry
Biotechnology
IPO Date
Jul 10, 2020
Stock Exchange
NASDAQ
Ticker Symbol
NKTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Nkarta stock is "Strong Buy." The 12-month stock price forecast is 77.25, which is an increase of 140.35% from the latest price.

Price Target
$77.25
(140.35% upside)
Analyst Consensus: Strong Buy